The Heart Failure Drug That Keeps Coming Back From the Dead
Relaxin has been chasing a heart failure breakthrough for over a decade, failing spectacularly each time. AstraZeneca thinks it finally cracked the code by turning an IV-only hormone into a daily pill, and the first real data just dropped.
A Pill Replaces the IV Bag
Relaxin has been the boy band of heart failure drugs: wildly hyped, repeatedly written off, and somehow still trying to make a comeback. But this time, the comeback might actually stick.
AstraZeneca just reported that its oral relaxin pill, AZD5462, showed encouraging signs in a mid-stage heart failure trial called LUMINARA. That might sound routine, but it's not. Relaxin has been one of the most tantalizing (and frustrating) targets in cardiology for over a decade. Every previous attempt to turn it into a real drug has crashed and burned. The difference now? Someone finally figured out how to put it in a pill.
Why Relaxin Keeps Haunting Cardiologists
To understand why this matters, you need a quick history lesson.
Relaxin is a natural hormone your body makes. Among other things, it relaxes blood vessels and reduces the strain on your heart. For years, researchers thought: what if we could give extra relaxin to people with heart failure and take some of the load off their struggling hearts? Think of it like loosening a belt that's cinched too tight around someone's chest.
The problem was always delivery. The original approach, developed by Novartis under the name serelaxin, required a 48-hour IV drip in the hospital. That's not a therapy you can scale to millions of chronic heart failure patients. It's more like a really expensive spa treatment you can only get in the ICU.
Still, early trials looked promising. The RELAX-AHF study showed serelaxin eased breathing difficulties and even hinted at a survival benefit. Cardiology Twitter (back when it was still Twitter) went wild. Novartis went all-in on a bigger trial.
Then came RELAX-AHF-2, and the dream died. Cardiovascular death rates were virtually identical: 8.7% with serelaxin versus 8.9% with placebo. The trial was a clean miss. Novartis walked away, and most of the field moved on.
Most of the field, but not AstraZeneca.
From Needle to Pill: The Science That Changed Everything
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
AstraZeneca's bet was that the target was right but the approach was wrong. Instead of flooding patients with a protein through an IV line, they built a small molecule that could activate the same receptor (called RXFP1) from inside a capsule you swallow with your morning coffee.
This is a bigger deal than it sounds. Relaxin is a peptide, a chain of amino acids that your stomach acid would destroy on contact. You can't just shrink it into a pill. So AstraZeneca's chemists took a completely different path: they designed an allosteric agonist, a small synthetic molecule that binds to a different spot on the receptor and flips the same biological switch. It's like finding a back door into a building when the front entrance is bricked shut.
The result is AZD5462, which AstraZeneca says is the first oral small molecule targeting relaxin biology to reach clinical trials. Before LUMINARA, AstraZeneca had also tried a long-acting injectable relaxin fusion protein called AZD3427, which was discontinued after a 260-patient phase 2 study. So the company was already 0-for-1 on relaxin when this readout came in.
What the LUMINARA Trial Actually Showed
LUMINARA enrolled 375 patients across 57 centers in 10 countries. Patients took one of three doses (20 mg, 80 mg, or 360 mg) or placebo every day for 24 weeks, all while continuing their standard heart failure medications.
The trial studied two groups of patients. In those with severely weakened hearts (ejection fraction ≤35%), the main question was whether AZD5462 could reverse harmful cardiac remodeling, the heart's slow, destructive reshaping under chronic stress. The lowest dose, 20 mg, showed the strongest signal, shrinking a key measure of heart size by 5.4 mL/m² more than placebo. That p-value landed at 0.054: just a hair above the traditional significance cutoff, but still a meaningful biological signal for a phase 2 study.
In patients with less severe heart failure (ejection fraction 41–55%), the drug's vasodilatory effects were clearer. All three doses significantly reduced vascular resistance, with the 80 mg dose cutting it by 21% versus baseline.
On safety, the news was reassuring. No excess side effects versus placebo. Blood pressure dipped slightly (expected, given the vasodilatory mechanism), but significant drops weren't more common in the drug group. And there was no sign of fluid overload, a concern that had haunted earlier relaxin attempts.
The Weird Dose-Response Puzzle
If you're paying close attention, you might have noticed something odd: the lowest dose worked best on the heart remodeling endpoint, while higher doses didn't clearly do more. That's a nonlinear dose-response, and it's the kind of thing that makes drug developers scratch their heads.
It's not necessarily a red flag. Biology is messy, and some receptors have a "Goldilocks zone" where more drug doesn't mean more benefit. But it does complicate the path forward. AstraZeneca will need to nail down the right dose before launching a massive (and expensive) phase 3 outcomes trial.
What Comes Next, and Why It Matters
Let's be clear about what LUMINARA did not prove. It didn't show that AZD5462 keeps people out of the hospital or helps them live longer. Those are the gold-standard endpoints in heart failure, and they require much bigger, longer trials to demonstrate. Investigator James Januzzi emphasized that larger studies are needed to determine real-world clinical benefit.
But the results do something important: they validate the mechanism. After serelaxin's flameout and AZD3427's quiet burial, AZD5462 is the first relaxin-targeting drug to show convincing biological activity in a well-designed, placebo-controlled study in years. And it's a pill, which means it could realistically be taken by millions of heart failure patients daily if phase 3 trials pan out.
The market opportunity is enormous. Heart failure affects roughly 64 million people worldwide, and even with the recent expansion of SGLT2 inhibitors (like dapagliflozin, which AstraZeneca already sells) across different heart failure subtypes, huge gaps remain. Patients with preserved ejection fraction still have very few proven options. Symptom relief remains inadequate for many.
AstraZeneca's Bigger Cardio Ambitions
AZD5462 doesn't exist in a vacuum. AstraZeneca has been quietly assembling a cardiovascular portfolio with the stated goal of becoming the global leader in CVRM (cardiovascular, renal, and metabolic) therapies by 2030. The company's pipeline includes assets for cardiorenal disease, a precision-medicine program for a rare genetic cardiomyopathy, and a recently licensed cholesterol-lowering compound from CSPC Pharmaceutical Group.
AZD5462 is one of the bigger bets in that portfolio, and a positive phase 3 readout could anchor AstraZeneca's heart failure franchise for the next decade.
For now, though, the oral relaxin pill has cleared its first real test. It's shown it can do biologically what the IV drip and the fusion protein couldn't sustain. The harder test, proving it actually changes patient outcomes, comes next. Relaxin's comeback tour has another show to play. Whether it's a curtain call or a headlining act depends entirely on what happens in phase 3.
Clinical & Regulatory
4 min read
GSK's Flu Shot Just Beat the Old Guard. Now Comes the Hard Part.
GSK's mRNA flu vaccine outperformed standard shots in Phase 2 and is heading to a pivotal Phase 3 trial. But history shows that better antibodies don't always mean better protection, and the road ahead is full of trap doors.
